KRAS Inhibitor Landscape
From "undruggable" to three approved drugs and a $24B acquisition target. KRAS mutations drive ~25% of all cancers. G12C is solved; G12D and pan-RAS are the new frontier. Revolution Medicines (RVMD) is the central name.
RAS Biology & the OFF vs. ON Paradigm
KRAS (Kirsten Rat Sarcoma viral oncogene) is the most frequently mutated oncogene in human cancer, present in ~20% of all cancers. KRAS mutations are particularly prevalent in pancreatic (>90%), colorectal (~40%), and lung (~25%) cancers.
KRAS cycles between an active GTP-bound “ON” state and an inactive GDP-bound “OFF” state. GEFs (mainly SOS1) activate KRAS by loading GTP. GAPs (mainly NF1) inactivate it by stimulating GTP hydrolysis. Oncogenic mutations impair GTP hydrolysis, locking KRAS in the ON state.
OFF-State Inhibitors
OFF-state inhibitors (sotorasib, adagrasib, divarasib, olomorasib, calderasib) bind a pocket that only exists when KRAS is GDP-bound (OFF). They must wait for the GTPase cycle to bring KRAS back to the inactive state. This creates a vulnerability: upstream RTK signaling pushes KRAS to the ON state, reducing target engagement.
ON-State Inhibitors (Revolution Medicines Platform)
ON-state inhibitors (daraxonrasib, elironrasib, zoldonrasib) use a novel tri-complex mechanism. The drug binds to cyclophilin A (a ubiquitous human protein), and this drug–cyclophilin complex then selectively recognizes and locks active GTP-bound KRAS. This is mechanistically analogous to how immunomodulatory drugs (lenalidomide) work through cereblon — a molecular chaperone recruitment approach.
Why ON-state matters: Because they target active KRAS directly, ON-state inhibitors don’t depend on the GDP/GTP cycle and may be inherently more resistant to adaptive resistance (which pushes KRAS toward the GTP state).
Degraders: A Third Modality
Degraders (Astellas setidegrasib/ASP3082) destroy the KRAS G12D protein entirely via targeted protein degradation using a VHL E3 ligase. The protein is eliminated rather than inhibited. Astellas is also developing ASP4396, a backup degrader using cereblon as the E3 ligase.
Pan-KRAS vs. Pan-RAS: Pan-KRAS inhibitors target multiple KRAS mutations (G12C, G12D, G12V, etc.) but not NRAS or HRAS. Pan-RAS inhibitors (like daraxonrasib) additionally block wild-type NRAS and HRAS, which matters for resistance since cancer cells can escape through WT RAS activation.
Competitive Pipeline by Mutation
KRAS G12C (NSCLC-dominant: ~12% NSCLC, ~3-4% CRC, ~1-2% PDAC)
| Drug | Company | Mechanism | Phase | Key Efficacy | Differentiator | Next Catalyst |
|---|---|---|---|---|---|---|
| Sotorasib (Lumakras) | Amgen | G12C OFF covalent | Approved | 41% ORR, 6.3mo PFS (NSCLC) | First-in-class. Now approved + panitumumab in CRC | Mature product — limited expansion |
| Adagrasib (Krazati) | BMS | G12C OFF covalent | Approved | 43% ORR, 6.9mo PFS (NSCLC) | 23hr half-life, BBB penetration | KRYSTAL-10 (CRC, H1 2026), KRYSTAL-7 (1L NSCLC, 2028) |
| Divarasib | Roche | G12C OFF covalent (next-gen) | Phase 3 | 59% ORR, 15.3mo PFS (NSCLC) | 5-20x more potent than sotorasib | KRASCENDO-1 (vs soto/ada, ~2027), KRASCENDO-2 (1L + pembro) |
| Olomorasib | Eli Lilly | G12C OFF covalent (next-gen) | Phase 3 | 35% ORR (solid tumors), 41% ORR post-G12Ci | Activity AFTER prior G12C failure (unique) | SUNRAY-01 (1L + pembro), SUNRAY-02 (resectable) |
| Calderasib (MK-1084) | Merck | G12C OFF covalent (next-gen) | Phase 3 | 38% ORR NSCLC, 38% CRC (Ph1) | Combo with Keytruda Qlex | KANDLELIT-007 (1L + Keytruda, just started Jan 2026) |
| Glecirasib | Jacobio / Innovent | G12C OFF covalent | Phase 3 (China) | China-focused development | Regional play | China data expected 2026 |
| Elironrasib (RMC-6291) | Revolution Medicines | G12C ON tri-complex | Phase 1/2 | BTD granted | Only ON-state G12C inhibitor. Designed for post-G12Ci relapse. | Combo with daraxonrasib (NCT06128551) |
KRAS G12D (PDAC-dominant: ~40% PDAC, ~12% CRC, ~4% NSCLC) — ZERO APPROVED DRUGS
| Drug | Company | Mechanism | Phase | Key Efficacy | Differentiator | Next Catalyst |
|---|---|---|---|---|---|---|
| Zoldonrasib (RMC-9805) | Revolution Medicines | G12D ON tri-complex | Phase 1 (pivotal-enabling) | 61% ORR NSCLC (n=18), 30% ORR PDAC (n=40) | First-ever BTD for G12D (Jan 2026). Tri-complex with cyclophilin A. | Pivotal data; potential accelerated filing |
| Setidegrasib (ASP3082) | Astellas | G12D degrader (VHL E3 ligase) | Phase 1 → Phase 3 planned | 58% ORR + chemo in 1L PDAC (n=12); 23% ORR mono NSCLC | First-in-class degrader. Eliminates protein entirely. | Phase 3 1L PDAC (setidegrasib + mFOLFIRINOX) starting 2026 |
| ASP4396 | Astellas | G12D degrader (cereblon ligase) | Phase 1 | Early | Backup degrader with different E3 ligase | Phase 1 data |
| HRS-4642 | Jiangsu HengRui | G12D inhibitor | Phase 3 (China) | China-focused | Regional play | Pivotal study China |
| VS-7375 (GFH375) | Verastem / GenFleet | G12D inhibitor | Phase 3 (China) | China 2L PDAC | Verastem-partnered | Ph3 China data |
| ARV-806 | Arvinas | G12D degrader | Phase 1 | Early — data expected 2026 | Third degrader entrant | Ph1 data 2026 |
Pan-KRAS / Pan-RAS (Broadest Coverage — All KRAS Mutations)
| Drug | Company | Mechanism | Phase | Key Efficacy | Differentiator | Next Catalyst |
|---|---|---|---|---|---|---|
| Daraxonrasib (RMC-6236) | Revolution Medicines | Pan-RAS ON multi-selective | Phase 3 | ~35% ORR PDAC (Ph1/2). BTD for PDAC. | Only pan-RAS(ON) inhibitor. Covers G12C/D/V, G13, Q61 + WT NRAS/HRAS. | RASolute-302 (2L PDAC, late 2026) — THE event of the year. RASolute-303 (1L PDAC, enrolling 2026). |
| JAB-23E73 | AstraZeneca / Jacobio | Pan-KRAS (not pan-RAS) | Phase 1/2 | Early | AZ paid $100M upfront Jan 2026. 600+ patients enrolling. | Ph1/2 data 2026-2027 |
| ERAS-4001 | Erasca / Joyo | Pan-KRAS | Phase 1 | Early | $12.5M upfront deal | Ph1 data |
| GFH276 | GenFleet | Pan-RAS | Phase 1 | Early | One of few pan-RAS after RVMD | Ph1 data |
Other Mutations (Expanding the Addressable Market)
| Drug | Company | Mutation | Phase | Status |
|---|---|---|---|---|
| RMC-5127 | Revolution Medicines | G12V ON | Phase 1 | Covers ~30% PDAC, ~7% NSCLC |
| RMC-0708 | Revolution Medicines | Q61H ON | Preclinical | Expanding mutation coverage |
| RMC-8839 | Revolution Medicines | G13C ON | Preclinical | Expanding mutation coverage |
Revolution Medicines Platform Deep-Dive
RVMD is unique in oncology: the only company with an ON-state RAS platform covering 6+ mutations across clinical and preclinical stages. It holds 3 FDA Breakthrough Therapy Designations across 3 different drugs (daraxonrasib for PDAC, elironrasib for G12C NSCLC, zoldonrasib for G12D NSCLC) — unprecedented for a pre-revenue company.
Platform economics: The tri-complex technology is modular. The same cyclophilin A chaperone recruitment mechanism is used with different warheads for different mutations. Each new drug leverages existing chemistry and manufacturing knowledge, compressing development timelines.
Financial position: ~$2B cash, pre-revenue, $24B market cap post-Merck collapse. The stock was ~$16B pre-M&A speculation, spiked to ~$28B during talks, and settled ~$24B after collapse.
| Asset | Target | Phase | Key Data | BTD | Next Catalyst |
|---|---|---|---|---|---|
| Daraxonrasib (RMC-6236) | Pan-RAS(ON) | Phase 3 | ~35% ORR PDAC (Ph1/2) | Yes (PDAC) | RASolute-302 late 2026 |
| Zoldonrasib (RMC-9805) | G12D(ON) | Phase 1 (pivotal) | 61% ORR NSCLC; 30% ORR PDAC | Yes (G12D NSCLC) | Pivotal data + accel. filing |
| Elironrasib (RMC-6291) | G12C(ON) | Phase 1/2 | Post-G12Ci activity | Yes (G12C NSCLC) | Combo w/ daraxonrasib |
| RMC-5127 | G12V(ON) | Phase 1 | Early | — | Ph1 data |
| RMC-0708 | Q61H(ON) | Preclinical | — | — | IND |
| RMC-8839 | G13C(ON) | Preclinical | — | — | IND |
The Merck Saga (January 2026)
Jan 7: WSJ reports AbbVie in acquisition talks (>$20B). RVMD +30%. AbbVie denies.
Jan 8: Zoldonrasib receives BTD for G12D NSCLC — RVMD’s 3rd BTD.
Jan 9: FT reports Merck in talks at $28-32B. Multiple outlets confirm.
Jan 12: JPM Healthcare Conference — intense speculation.
Jan 26: Talks collapse. RVMD -20%, settles ~$24B market cap.
Management chose independence, signaling confidence that RASolute-302 data will justify a higher valuation. CEO Mark Goldsmith MD/PhD: “It’s not our goal to build something big. It’s our goal to build something impactful.”
RVMD Bull Case
- If RASolute-302 positive in PDAC, daraxonrasib becomes the first-ever targeted therapy in pancreatic cancer
- RVMD re-rates to $40B+ and renewed bidding war from multiple Big Pharma
- Platform covers ~3.4M new KRAS-mutant cancer patients/year worldwide
- 3 BTDs across 3 drugs with modular platform chemistry — pipeline depth is unmatched
RVMD Bear Case
- PDAC has been a graveyard for targeted therapies — decades of failures
- Pan-RAS inhibition of WT KRAS may have a narrow therapeutic window (WT KRAS is essential for normal development)
- Small datasets with unconfirmed responses (6/11 NSCLC responses for zoldonrasib were unconfirmed)
- $24B valuation for a pre-revenue company with no approved products
Resistance Biology
Adaptive resistance (hours): When you inhibit mutant KRAS, ERK-mediated negative feedback is relieved. This reactivates the RAS-MAPK pathway through WT NRAS and HRAS via RTK → SOS1 signaling. This is the fundamental problem with ALL KRAS inhibitors.
Why OFF-state inhibitors are especially vulnerable: Adaptive resistance pushes KRAS toward the GTP-bound ON state, which reduces the target available for OFF-state drugs to bind. The drug literally has less target to work with.
Why ON-state inhibitors may be more durable: They bind GTP-bound KRAS directly. Feedback that pushes KRAS to the ON state may paradoxically increase target engagement (more ON-state KRAS = more binding sites).
Tissue-specific differences: CRC has much stronger RTK (especially EGFR) feedback than NSCLC, explaining why KRAS monotherapy ORR is ~30% in CRC vs ~40-55% in NSCLC. This is why sotorasib + panitumumab (anti-EGFR) was developed specifically for CRC.
Acquired Resistance Mutations
Y96D, Y96S alter the Switch II pocket, blocking covalent binding. Some confer cross-resistance to both sotorasib and adagrasib. Others remain sensitive to the alternative G12C inhibitor. Pathway bypass through BRAF amplification, MET amplification, PIK3CA mutation, or histologic transformation (NSCLC → SCLC) represents a distinct resistance category.
Implication: Monotherapy will inevitably fail. Combinations that block upstream feedback (SHP2i, SOS1i, EGFRi) or downstream bypass (MEKi, CDK4/6i) are necessary for durable responses.
Combination Therapy Landscape
| Strategy | Rationale | Key Trials | Status |
|---|---|---|---|
| G12C + anti-PD-1 (1L NSCLC) | Expand to frontline, largest commercial market | Olomorasib+pembro (SUNRAY-01), divarasib+pembro (KRASCENDO-2), calderasib+Keytruda Qlex (KANDLELIT-007) | Multiple Phase 3s enrolling — THE commercial prize |
| G12C + EGFRi (CRC) | Block EGFR-driven feedback in CRC | Soto+panitumumab (FDA approved), divarasib+cetuximab (62% ORR Ph1b) | Validated in CRC — soto+pani already approved |
| G12C + SHP2i | Block convergent RTK feedback upstream of SOS1 | JDQ443+TNO155 (KontRASt-01) | Tolerability challenges — some programs discontinued |
| G12C + SOS1i | Alternative to SHP2i, block RAS activation directly | BI-1701963+BI 1823911 | Early clinical; mixed results |
| G12D + chemo (1L PDAC) | Frontline PDAC — highest unmet need | Setidegrasib+mFOLFIRINOX (Phase 3 planned 2026) | 58% ORR in Phase 1 is attention-getting |
| Pan-RAS + G12C-selective | Deep RAS suppression by blocking both mutant AND WT RAS | Daraxonrasib+elironrasib (NCT06128551) | Phase 1/2 — rational but unproven |
Big Pharma Oncology Gaps & KRAS M&A Logic
Understanding who needs KRAS assets and why is critical for anticipating M&A. Most large pharma companies face patent cliffs on blockbuster drugs within 2-4 years. KRAS is one of the few areas with sufficient market size ($7-8B by 2034) and clinical momentum to replace lost revenue.
| Company | Key LOE Drug | LOE Date | Revenue at Risk | KRAS Asset | Strategic Gap |
|---|---|---|---|---|---|
| Merck | Keytruda | 2028 | ~$30B/yr | Calderasib (G12C OFF, Ph3) | No G12D, no pan-RAS. Tried RVMD at $30B — failed. $70B opportunity target by mid-2030s. |
| BMS | Eliquis + Opdivo | 2026/2028 | ~$16B combined | Krazati (G12C OFF, approved) | Gen 1 product being surpassed. No G12D. Cannot afford mega-deal. |
| AstraZeneca | Farxiga | 2026 | ~$7.7B | JAB-23E73 (pan-KRAS, Ph1/2) | Late entrant, $100M bolt-on. Playing catch-up. |
| Eli Lilly | (No major onc LOE) | — | — | Olomorasib (G12C OFF, Ph3) | Strongest position — can build internally. No G12D or pan-RAS. |
| Roche | (Diverse) | Gradual | — | Divarasib (G12C OFF, Ph3) | Best-in-class G12C (59% ORR). No G12D or pan-RAS. |
| Pfizer | Ibrance/Xtandi | 2027 | ~$8B | None | Complete KRAS gap. Focused on ADCs post-Seagen. |
| Astellas | — | — | — | Setidegrasib (G12D degrader) | Only degrader company — could be acquired itself. |
Every major pharma with a KRAS asset has a G12C OFF-state inhibitor. None except RVMD has a viable ON-state platform or pan-RAS coverage. G12D has ZERO approved drugs. This is why RVMD commanded a $30B valuation — it is the only company with ON-state mechanism + pan-RAS + G12D + G12C + G12V coverage. If RASolute-302 data are positive, expect a renewed bidding war. If data disappoint, the G12C OFF-state companies (Roche, Lilly, Merck) become dominant and RVMD’s $24B valuation becomes untenable.
Market Opportunity by Indication & Mutation
| Cancer Type | US Annual Incidence | % KRAS Mutated | Dominant Mutations | Addressable Market | Current SOC |
|---|---|---|---|---|---|
| NSCLC | ~236,000 | ~25% | G12C (12%), G12V (7%), G12D (4%) | $10-15B (1L combos) | Keytruda ± chemo |
| PDAC | ~64,000 | >90% | G12D (40%), G12V (30%), G12R (15%) | $5-8B | FOLFIRINOX, gem/nab-P. No targeted therapy EVER worked. |
| CRC | ~153,000 | ~40% | G12D (12%), G12V (8%), G12C (3-4%), G13D (7%) | $3-5B | Chemo + biologics |
| LGSOC | Rare subset | KRAS mutated | Various | <$1B | Avutometinib+defactinib (approved May 2025) |
Total KRAS-mutant cancer worldwide: ~3.4 million new patients per year. KRAS inhibitors market projected to grow from ~$526M (2025) to ~$7.8B by 2034 at 35% CAGR.
Pancreatic Cancer Context
5-year survival ~12%. Third leading cause of cancer death in the US. Despite 40+ years of trials, the standard of care remains cytotoxic chemotherapy. There has never been a successful targeted therapy in PDAC. If daraxonrasib or zoldonrasib show meaningful Phase 3 activity, it would be the first time any targeted drug works in this disease. This is why the market prices RVMD at $24B pre-revenue.
Deal Landscape
| Deal | Parties | Date | Value | Significance |
|---|---|---|---|---|
| Merck-RVMD (collapsed) | Merck + Revolution Medicines | Jan 2026 | $28-32B range | Largest attempted biotech deal of 2026. Collapsed Jan 26 — RVMD chose independence. |
| AZ-Jacobio | AstraZeneca + Jacobio | Jan 2026 | $100M upfront | Pan-KRAS bolt-on. Signals Big Pharma consensus on KRAS. |
| BMS-Mirati | BMS acquired Mirati | 2024 | $4.8B | For adagrasib (Krazati). Now looks modest vs RVMD valuations. |
| RVMD-Royalty Pharma | Revolution Medicines + RP | 2025 | $2B | Royalty financing — RVMD monetized future royalties to fund pipeline. |
| Bayer-Kumquat | Bayer + Kumquat Biosciences | 2025 | Undisclosed | KRAS G12D partnership. |
| Verastem-GenFleet | Verastem + GenFleet | 2024 | Undisclosed | VS-7375 G12D partnership. |
Completed Catalysts
Upcoming Catalysts
Key Sources
- Sacher A et al. “Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.” NEJM 2023; 389:710-721. NCT04449874
- Skoulidis F et al. “Sotorasib for Lung Cancers with KRAS p.G12C Mutation.” (CodeBreaK 100) NEJM 2021; 384:2371-2381. PubMed
- Li BT et al. “Adagrasib in Patients with KRAS G12C-Mutated NSCLC.” (KRYSTAL-1 updated) NEJM 2024. PubMed
- Strickler JH et al. “Sotorasib plus Panitumumab in KRAS G12C CRC.” (CodeBreaK 300) NEJM 2023; 389:2125-2139. PubMed
- Revolution Medicines. “Zoldonrasib AACR 2025 — 61% ORR in G12D NSCLC.” doi:10.1158/1538-7445.AM2025-CT019
- Astellas. “Setidegrasib + mFOLFIRINOX in 1L PDAC.” ASCO-GI 2026 presentation.
- “Emerging landscape of KRAS inhibitors.” (Comprehensive review) Cancer Cell Jan 2026.
- Hofmann MH et al. “Expanding biology of SOS1 in KRAS-driven cancers.” Nature Cancer 2024.
- “Astra enters the pan-KRAS game.” ApexOnco / OncologyPipeline, Jan 2026.
- KANDLELIT-007 Phase 3 design. NCT07190248
- RASolute-302 Phase 3. ClinicalTrials.gov
- Sacher A et al. “Divarasib long-term follow-up — 59% ORR, 15.3mo PFS.” JCO 2025.